H2i client ImmunoBiochem winners in the RESI Innovation Challenge

We are pleased to share some great news – ImmunoBiochem has won second place in the RESI Innovation Challenge during the JPM Healthcare Conference Week in San Francisco.

ImmunoBiochem is a privately held biopharmaceutical company solving the problem of tumor heterogeneity by targeting unique proteins enriched in the secretomes of cancer cells with Antibody Drug Conjugates (ADCs) – a promising class of biological anticancer therapeutics. ImmunoBiochem has identified a class of molecular targets that are secreted by cancer cells, but not healthy cells, and possess unique properties enabling the highly-selective delivery of toxic payloads to cancer cells, while leaving normal cells unharmed. ImmunoBiochem’s next-generation biologics aim to offer a superior safety profile and broad therapeutic window. Lead candidate, IMB-212, is aimed at a well-characterized cancer biomarker supported by a wealth of clinical data, and is being developed for Triple-Negative Breast Cancer (TNBC) – an aggressive disease for which no targeted biologics treatment options are available.

Read more here